LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated β-catenin dephosphorylation in a subset of stem-like bladder cancer cells

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA 71 209-249

[2] Ferlay J(2022)Cancer statistics in China and United States, 2022: profiles, trends, and determinants Chin Med J (Engl) 135 584-590

[3] Siegel RL(2020)Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer J Clin Invest 130 6278-6289

[4] Laversanne M(2000)Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068-3077

[5] Soerjomataram I(2003)Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 7265-7279

[6] Jemal A(2012)Molecular mechanisms of cisplatin resistance Oncogene 31 1869-1883

[7] Bray F(2016)Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation Drug Resistance Updates 24 34-54

[8] Xia C(2018)Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma Cell Oncol (Dordr) 41 185-200

[9] Dong X(2020)Targeting the Wnt/β-catenin signaling pathway in cancer J Hematol Oncol 13 165-50

[10] Li H(2018)Sphingolipid metabolism in cancer signalling and therapy Nat Rev Cancer 18 33-185

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA 71 209-249

[2] Ferlay J(2022)Cancer statistics in China and United States, 2022: profiles, trends, and determinants Chin Med J (Engl) 135 584-590

[3] Siegel RL(2020)Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer J Clin Invest 130 6278-6289

[4] Laversanne M(2000)Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068-3077

[5] Soerjomataram I(2003)Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 7265-7279

[6] Jemal A(2012)Molecular mechanisms of cisplatin resistance Oncogene 31 1869-1883

[7] Bray F(2016)Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation Drug Resistance Updates 24 34-54

[8] Xia C(2018)Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma Cell Oncol (Dordr) 41 185-200

[9] Dong X(2020)Targeting the Wnt/β-catenin signaling pathway in cancer J Hematol Oncol 13 165-50

[10] Li H(2018)Sphingolipid metabolism in cancer signalling and therapy Nat Rev Cancer 18 33-185